Leslie Popplewell

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell et al. · New England Journal of Medicine · 2018 · 1.1K citations · Full text

Life Sciences, Immunology, Oncology +17

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown et al. · Journal of Clinical Oncology · 2011 · 643 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Fowler, Michael Dickinson, Martin Dreyling et al. · Nature Medicine · 2021 · 527 citations · Full text

Medicine, Hematology, Oncology +12

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

Michael C. Jensen, Leslie Popplewell, Laurence J.N. Cooper et al. · Biology of Blood and Marrow Transplantation · 2010 · 522 citations · Full text

Life Sciences, Immunology, Oncology +15

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Michael Andreeff, Kevin R. Kelly, Karen Yee et al. · Clinical Cancer Research · 2015 · 353 citations

Medicine, Oncology, Pharmacology +17